Noselab has developed a proprietary platform making biomarker signatures of central nervous system (CNS) diseases accessible through a previously untapped biological
gateway: the brain–nose interface (BNI) and nasal fluid.

By enabling direct, minimally invasive access to CNS-related molecular signals, Noselab is pioneering a paradigm shift in understanding, diagnosing, monitoring and
treatment of brain diseases.

Our integrated clinical network, combined with advanced analytics and data-driven approaches, allows for precise patient stratification, longitudinal biomarker tracking,
and correlation of molecular signatures with real-world clinical outcomes.

Noselab is building the foundation for an entirely new category in CNS disease management. We are partnering with biopharma, clinicians, and research institutions to
accelerate drug development, improve diagnostic results, and unlock more personalized treatment strategies – for the benefit of patients, society, and
shareholders alike.